This concept is supported by retrospectives studies reporting a possible improvement of fibrosis by ACE inhibitors in patients with hepatitis C and patients with NASH without major safety issues (43–45). The gene discussed is ACE; the disease is metabolic dysfunction-associated steatohepatitis.